Page 38 - Mobile Opera News Today

The FDA has approved VIVJOA — the first medication for recurrent vulvovaginal candidiasis — for use in permanently infertile and postmenopausal women, according to a Mycovia Pharmaceuticals press release.

Influenza vaccination coverage in adults with early rheumatoid arthritis in Canada remains “suboptimal,” according to data published in ACR Open Rheumatology.

The FDA proposed prohibiting menthol cigarettes and flavored cigars. The new product standards are designed to substantially prevent disease and death from combusted product use and to prevent young people from starting to smoke.“The proposed rules would help prevent children from becoming the next generation of smokers and help adult smokers quit,” HHS Secretary Xavier Becerra said

Tanezumab and NSAIDs both demonstrated early and sustained improvement in pain and function among patients with knee or hip osteoarthritis, according to data published in Arthritis Research and Therapy.

Ganaxolone was generally well tolerated and significantly reduced the frequency of seizures associated with CDKL5 deficiency disorder, according to a study published in The Lancet Neurology. “[CDKL5 deficiency disorder (CDD)] is a developmental and epileptic encephalopathy characterized by early-onset, refractory seizures and severe global developmental impairment,” Elia M. Pestana

DALLAS — Targeted sequencing appears to be a promising strategy for molecular profiling of head and neck squamous cell carcinoma, according to study results.The findings — presented at American Head & Neck Society Annual Meeting — showed a correlation between detection of circulating tumor DNA (ctDNA) and pathological adverse features.

The FDA granted breakthrough therapy designation to fam-trastuzumab deruxtecan-nxki for treatment of adults with unresectable or metastatic HER2-low breast cancer, according to a press release from the agent’s manufacturer.The designation applies to use of the HER2-directed antibody-drug conjugate by patients who previously received a systemic therapy in the metastatic setting or

The FDA has granted orphan drug designation to Gesynta Pharma’s GS-248, an oral small molecule, selective membrane-associated prostaglandin E synthase-1 (mPGES-1) inhibitor, for systemic sclerosis, according to a company press release.

Oral calcium supplementation with or without vitamin D was associated with lower survival and a greater need for aortic valve replacement among older patients with mild to moderate aortic stenosis, researchers reported.In a large, retrospective analysis with extended follow-up, researchers also found that CV mortality was higher among older patients with mild to moderate aortic stenosis who were

WASHINGTON — A phase 2 study found that ST-100, a collagen mimetic peptide, could provide a new avenue for treatment of dry eye disease, according to a presenter at the American Society of Cataract and Refractive Surgery meeting.